Curient, Approval Granted for Phase 2 Clinical Trial Plan of COVID-19 Treatment Candidate Telacebec
[Asia Economy Reporter Minji Lee] Curient announced on the 24th that it has received approval from the South African Health Products Regulatory Authority for the Phase 2 clinical trial plan of its COVID-19 treatment candidate, Telacebec.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Court Dismisses Pastor Jun Kwanghoon's Request to Stay Execution of Travel Ban
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "We plan to verify the efficacy, pharmacokinetics, safety, and biomarker changes of Telacebec when administered to patients with COVID-19 disease."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
